^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carmustine

    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    5d
    Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) (clinicaltrials.gov)
    P1, N=20, Recruiting, Washington University School of Medicine | Trial completion date: Nov 2026 --> Jun 2031 | Trial primary completion date: Aug 2026 --> Mar 2031
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • topotecan • carmustine
    10d
    A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma (clinicaltrials.gov)
    P2, N=49, Recruiting, VIVUS LLC | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    carmustine
    18d
    IELSG32: Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (clinicaltrials.gov)
    P2, N=227, Completed, International Extranodal Lymphoma Study Group (IELSG) | N=126 --> 227
    Enrollment change
    |
    Rituxan (rituximab) • cytarabine • carmustine • thiotepa • methotrexate IV
    1m
    A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: Sep 2026 --> Sep 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cytarabine • carmustine • melphalan
    1m
    A network-driven computational framework for identifying FDA-approved drug repurposing across heterogeneous brain cancers. (PubMed, Front Mol Biosci)
    As a result, three repurposed drugs were identified as priorities: (i) mefloquine (reference drug: vorasidenib citrate), (ii) clofibric acid (reference drug: carmustine), and armillarisin A (reference drug: lomustine). These results also suggest repurposing candidates for synergistic combinations across different brain tumors. The two applications developed in this work are freely accessible and in the public domain at https://assay.smallmoles.com/escorwin.
    FDA event • Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • KDR (Kinase insert domain receptor) • CDK1 (Cyclin-dependent kinase 1)
    |
    lomustine • carmustine • Voranigo (vorasidenib)
    1m
    Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)
    2ms
    ALK-positive ALCL: first described adult case of synchronous CNS and systemic involvement at presentation: a case report and review of the literature. (PubMed, Br J Neurosurg)
    The patient was treated with a modified MARIETTA protocol (without rituximab) and consolidated with a carmustine-based autologous stem cell transplant. shows complete metabolic response on PET-CT and MRI brain. This case presents the first successful treatment of a synchronous presentation of CNS and systemic ALK-positive ALCL, and the importance of a multidisciplinary approach for diagnosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • NPM1 (Nucleophosmin 1) • TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    ALK positive • ALK fusion • ALK translocation
    |
    Rituxan (rituximab) • carmustine
    2ms
    SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells (clinicaltrials.gov)
    P1, N=24, Recruiting, General Oncology, Inc. | N=10 --> 24 | Trial completion date: Aug 2027 --> Dec 2028 | Trial primary completion date: Aug 2026 --> Dec 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • PALB2 mutation
    |
    carmustine • melphalan • Mustargen (mechlorethamine)
    3ms
    CALGB 51101: Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=113, Active, not recruiting, Alliance for Clinical Trials in Oncology
    Trial completion date
    |
    cytarabine • etoposide IV • carmustine • thiotepa
    3ms
    Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma (clinicaltrials.gov)
    P1, N=50, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jan 2027 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    temozolomide • carmustine • Zynyz (retifanlimab-dlwr)
    3ms
    Development of a fatty acid metabolism (FAM)-related gene signature for prognosis prediction and personalized therapy in lower grade gliomas. (PubMed, Transl Cancer Res)
    Drug sensitivity analysis indicated that high-risk individuals might be more responsive to chemotherapy, particularly temozolomide and carmustine. This study underscores the prognostic role of the FAM-related risk model for LGGs. Assessing patient risk scores through this model could help tailor personalized treatments, providing valuable guidance for clinical decision-making.
    Journal • Gene Signature • IO biomarker
    |
    CPT2 (Carnitine Palmitoyltransferase 2)
    |
    temozolomide • carmustine
    3ms
    Unraveling the Molecular Mechanisms of Glioma Recurrence: A Study Integrating Single-Cell and Spatial Transcriptomics. (PubMed, Ann Clin Transl Neurol)
    Fibroblasts drive glioma recurrence, with AEBP1, ZNF708, and TSHZ2 predicting recurrence and chemoresistance. These genes promote immune suppression (via plasma cells) and activate recurrence pathways. Oligodendrocyte-astrocyte interactions shape the recurrent microenvironment, suggesting new therapeutic targets.
    Journal • IO biomarker
    |
    AEBP1 (AE Binding Protein 1) • IL17A (Interleukin 17A)
    |
    cisplatin • irinotecan • vincristine • carmustine